Effect of PSI‐697, a Novel P‐Selectin Inhibitor, on Platelet–Monocyte Aggregate Formation in Humans
Open Access
- 23 January 2013
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 2 (1) , e006007
Abstract
Background: Platelet activation is central to the pathogenesis of acute coronary syndromes. Surface expression ofP‐selectin on activated platelets induces formation of platelet–monocyte aggregates and promotes vascular inflammation and thrombosis.P‐selectin antagonism may represent a novel therapeutic strategy in vascular disease. We aimed to investigate the effects of the novelP‐selectin antagonistPSI‐697 on platelet–monocyte aggregate formation in humans.Methods and Results: In a double‐blind, randomized, placebo‐controlled crossover study, healthy smokers were randomized to receive either oralPSI‐697 600 mg or matched placebo. The sequence of treatment was also randomized, with all subjects receiving bothPSI‐697 and placebo. Platelet–monocyte aggregates were measured by flow cytometry at 4 and 24 hours in the presence and absence of thrombin receptor‐activating peptide (TRAP; 0.1 to 1.0 μm/L). Theex vivoaddition ofTRAPcaused a concentration‐dependent increase in platelet–monocyte aggregates from 8.2% to 94.8% (PPP>0.05).P‐selectin‐blocking antibody (CLB‐Thromb6), but notPSI‐697, inhibited both stimulated and unstimulated platelet–monocyte aggregate formation in vitro (P<0.001).Conclusions: The novel small‐moleculeP‐selectin antagonistPSI‐697 did not inhibit basal or stimulated platelet–monocyte aggregate formation in humans at the dose tested. Its clinical efficacy remains to be established.Clinical Trial Registration: URL:http://EudraCT.ema.europa.euUnique identifier: 2007‐005695‐14.Keywords
This publication has 31 references indexed in Scilit:
- P‐selectin antagonism reduces thrombus formation in humansJournal of Thrombosis and Haemostasis, 2009
- Characterization of the Novel P-Selectin Inhibitor PSI-697 [2-(4-Chlorobenzyl)-3-hydroxy-7,8,9,10-tetrahydrobenzo[h] Quinoline-4-carboxylic acid] in Vitro and in Rodent Models of Vascular Inflammation and ThrombosisThe Journal of Pharmacology and Experimental Therapeutics, 2008
- Flow cytometric analysis of circulating platelet-monocyte aggregates in whole blood: Methodological considerationsThrombosis and Haemostasis, 2007
- Treatment with an oral small molecule inhibitor of P selectin (PSI-697) decreases vein wall injury in a rat stenosis model of venous thrombosisJournal of Vascular Surgery, 2006
- Smoking is associated with advanced coronary atherosclerosis in youthAtherosclerosis, 2005
- Platelet Function Testing in Cardiovascular DiseasesCirculation, 2004
- Increased CD40 ligand and platelet–monocyte aggregates in patients with type 1 diabetes mellitusAtherosclerosis, 2004
- Accumulation of Tissue Factor into Developing Thrombi In Vivo Is Dependent upon Microparticle P-Selectin Glycoprotein Ligand 1 and Platelet P-SelectinJournal of Experimental Medicine, 2003
- Effects of efonidipine on platelet and monocyte activation markers in hypertensive patients with and without type 2 diabetes mellitusJournal of Human Hypertension, 2002
- Traffic signals for lymphocyte recirculation and leukocyte emigration: The multistep paradigmCell, 1994